Engineering health
how biotechnology changed medicine
| LEADER | cam a22 4 4500 | ||
|---|---|---|---|
| 001 | 528973045 | ||
| 003 | CHVBK | ||
| 005 | 20201001101731.0 | ||
| 008 | 180926s2018 enka b||| 001 0 eng| | ||
| 010 | |a 2017302921 | ||
| 016 | 7 | |a 101721119 |2 DNLM | |
| 020 | |a 978-1-78262-084-6 |q paperback | ||
| 020 | |a 1-78262-084-2 |q paperback | ||
| 020 | |z 978-1-78801-234-8 |q epub | ||
| 035 | |a (IDSBB)006817185 | ||
| 035 | |a (NEBIS)011067017 | ||
| 035 | |a (OCoLC)1012811607 |z (OCoLC)989968279 | ||
| 035 | |a (OCoLC)989968279 | ||
| 040 | |a NLM |b ger |c NLM |d LTSCA |d OCLCF |d YDX |d GPRCL |d ITD |d OCLCO |d DLC |d BTCTA |d BDX |d EUM |d OCLCO |d SzZuIDS BS/BE B452 |e rda | ||
| 050 | 4 | |a R856 |b .E44 2018 | |
| 060 | 0 | 0 | |a 2018 A-936 |
| 060 | 1 | 0 | |a W 82 |
| 082 | 1 | |a 610 |2 15 | |
| 082 | 0 | 4 | |a 610.28 |2 23 |
| 082 | 0 | |a a610.28 |2 23 | |
| 245 | 0 | 0 | |a Engineering health |b how biotechnology changed medicine |c edited by Lara V. Marks |
| 264 | 1 | |a London |b The Royal Society of Chemistry |c [2018] | |
| 300 | |a xii, 267 Seiten |b Illustrationen |c 23 cm | ||
| 504 | |a Includes bibliographical references and subject index | ||
| 520 | |a Biotechnology harnesses cellular and biochemical systems to advance knowledge of the molecular cause of disease and to provide new diagnostic tools and more precisely targeted drugs. Within a decade, global investment in medical biotechnology has increased more than ten-fold, resulting in therapies for previously untreatable conditions. But what exactly is biotechnology and what are its origins? What further benefits to human health could it offer in the future? In an accessible style, this book examines how biotechnology tools came to be discovered, how they are being used, and what the future of medicine could look like. Experts trace the development of biotechnologies such as DNA sequencing, gene therapy and monocolonal antibodies explaining how they are applied in medicine to combat disease. Find out about the science behind diagnostic technologies, such as cancer screening and pregnancy tests. Explore how genetic engineering has produced new vaccines. Applying new biotechnologies in medicine is not without great challenges. As medicines shift from small organic molecules to large, complex structures, such as therapeutic proteins, drugs become difficult to make, administer and regulate. This book will intrigue anyone who is interested in medicine and how we have been, and may continue to, engineer better health for ourselves | ||
| 650 | 7 | |a Biomedizinische Technik |0 (DE-588)4006882-1 |2 gnd | |
| 650 | 7 | |a Biotechnologie |0 (DE-588)4069491-4 |2 gnd | |
| 650 | 7 | |a Medizin |0 (DE-588)4038243-6 |2 gnd | |
| 650 | 7 | |a Pharmazeutische Chemie |0 (DE-588)4132158-3 |2 gnd | |
| 650 | 0 | |a Biotechnology | |
| 650 | 2 | |a Biomedical Technology |0 (DNLM)D020811 | |
| 650 | 7 | |a Biotechnology |2 fast | |
| 650 | 0 | |a Biomedical engineering | |
| 650 | 7 | |a BIOCHEMISCHE BIOTECHNOLOGIE |x ger |0 (ETHUDK)000044563 |2 ethudk | |
| 650 | 7 | |a GENETISCHE THERAPIEN (MEDIZIN) |x ger |0 (ETHUDK)000042933 |2 ethudk | |
| 650 | 7 | |a IMMUNPHARMAKOLOGIE + IMMUNTHERAPIE + IMMUNPROPHYLAXE + IMMUNOLOGISCHE PRÄPARATE |x ger |0 (ETHUDK)000026787 |2 ethudk | |
| 650 | 7 | |a MEDIZINISCHE BIOCHEMIE + MEDIZINISCHE MOLEKULARBIOLOGIE |x ger |0 (ETHUDK)000021734 |2 ethudk | |
| 650 | 7 | |a MONOKLONALE ANTIKÖRPER (IMMUNOLOGISCHE TECHNIKEN) |x ger |0 (ETHUDK)000038652 |2 ethudk | |
| 650 | 7 | |a SYNTHETISCHE BIOLOGIE |x ger |0 (ETHUDK)000066277 |2 ethudk | |
| 650 | 7 | |a ZIELGERICHTETE ARZNEIMITTEL (PHARMAKOLOGIE) |x ger |0 (ETHUDK)000039312 |2 ethudk | |
| 691 | 7 | |B u |a BIOCHEMISCHE BIOTECHNOLOGIE |z ger |u 573.6.002.577.1 |2 nebis E1 | |
| 691 | 7 | |B u |a MEDIZINISCHE BIOCHEMIE + MEDIZINISCHE MOLEKULARBIOLOGIE |z ger |u 61.001'577 |2 nebis E1 | |
| 691 | 7 | |B u |a MONOKLONALE ANTIKÖRPER (IMMUNOLOGISCHE TECHNIKEN) |z ger |u 612.017.1,9.001.5.083.31.082.261 |2 nebis E1 | |
| 691 | 7 | |B u |a ZIELGERICHTETE ARZNEIMITTEL (PHARMAKOLOGIE) |z ger |u 615.031 |2 nebis E1 | |
| 691 | 7 | |B u |a GENETISCHE THERAPIEN (MEDIZIN) |z ger |u 616-085-056.7 |2 nebis E1 | |
| 691 | 7 | |B u |a IMMUNPHARMAKOLOGIE + IMMUNTHERAPIE + IMMUNPROPHYLAXE + IMMUNOLOGISCHE PRÄPARATE |z ger |u 615.37 |2 nebis E1 | |
| 691 | 7 | |B u |a SYNTHETISCHE BIOLOGIE |z ger |u 577*4 |2 nebis E1 | |
| 691 | 7 | |B u |a BIOCHEMICAL ENGINEERING |z eng |u 573.6.002.577.1 |2 nebis E1 | |
| 691 | 7 | |B u |a GÉNIE BIOCHIMIQUE |z fre |u 573.6.002.577.1 |2 nebis E1 | |
| 691 | 7 | |B u |a BIOCHIMIE MÉDICALE + BIOLOGIE MOLÉCULAIRE MÉDICALE |z fre |u 61.001'577 |2 nebis E1 | |
| 691 | 7 | |B u |a MEDICAL BIOCHEMISTRY + MEDICAL MOLECULAR BIOLOGY |z eng |u 61.001'577 |2 nebis E1 | |
| 691 | 7 | |B u |a ANTICORPS MONOCLONAUX (TECHNIQUES IMMUNOLOGIQUES) |z fre |u 612.017.1,9.001.5.083.31.082.261 |2 nebis E1 | |
| 691 | 7 | |B u |a MONOCLONAL ANTIBODIES (IMMUNOLOGICAL TECHNIQUES) |z eng |u 612.017.1,9.001.5.083.31.082.261 |2 nebis E1 | |
| 691 | 7 | |B u |a MÉDICAMENTS CIBLÉS (PHARMACOLOGIE) |z fre |u 615.031 |2 nebis E1 | |
| 691 | 7 | |B u |a TARGETED DRUGS (PHARMACOLOGY) |z eng |u 615.031 |2 nebis E1 | |
| 691 | 7 | |B u |a THÉRAPIES GÉNIQUES (MÉDECINE) |z fre |u 616-085-056.7 |2 nebis E1 | |
| 691 | 7 | |B u |a GENETIC THERAPIES (MEDICINE) |z eng |u 616-085-056.7 |2 nebis E1 | |
| 691 | 7 | |B u |a IMMUNOPHARMACOLOGIE + IMMUNOTHÉRAPIE + MÉDICAMENTS IMMUN0LOGIQUES + MÉDICAMENTS IMMUNOPROPHYLACTIQUES |z fre |u 615.37 |2 nebis E1 | |
| 691 | 7 | |B u |a IMMUNOTHERAPY + IMMUNOPHARMACOLOGY + IMMUNOLOGIC MEDICAMENTS + IMMUNOPROPHYLACTIC AGENTS |z eng |u 615.37 |2 nebis E1 | |
| 691 | 7 | |B u |a SYNTHETIC BIOLOGY |z eng |u 577*4 |2 nebis E1 | |
| 691 | 7 | |B u |a BIOLOGIE SYNTHÉTIQUE |z fre |u 577*4 |2 nebis E1 | |
| 700 | 1 | |a Marks |D Lara |d 1963- |0 (DE-588)131650432 |e Herausgeber |4 edt | |
| 898 | |a BK020000 |b XK020000 |c XK020000 | ||
| 909 | 7 | |a Stoppsignal FRED |2 nebis DS | |
| 912 | 7 | |a 033 |2 E01-20180129 | |
| 912 | 7 | |a 130 |2 E01-20180129 | |
| 949 | |B NEBIS |F E01 |b E01 |c MG |j T 80292 | ||
| 949 | |B IDSBB |F B452 |b B452 |c 452LB |j MED_W_82 10 |x NELB4521809 | ||
| 950 | |B IDSBB |P 700 |E 1- |a Marks |D Lara |d 1963- |0 (DE-588)131650432 |e Herausgeber |4 edt | ||
| 950 | |B NEBIS |P 700 |E 1- |a Marks |D Lara |d 1963- |0 (DE-588)131650432 |e Herausgeber |4 edt | ||
| 956 | 4 | |B NEBIS |C EAD50 |D EBI01 |a E01 |u https://opac.nebis.ch/objects/pdf03/e01_978-1-78262-084-6_01.pdf |y Titelblatt und Inhaltsverzeichnis |x VIEW |q pdf | |